StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3084% below fair value
$1.05−0.02 (-1.87%)

Close on Nov 20, 2026Market cap $33.01MP/E 2.9Yield –

Actinium Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Actinium Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $90.00K. For fiscal 2025 it was $90.00K, up 11.1% from the year before. The highest annual figure on record is $1.14M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.00K+11.1%
FY2023Dec 31, 2023$81.00K-92.1%
FY2022Dec 31, 2022$1.03M-10.0%
FY2021Dec 31, 2021$1.14M–
FY2011Dec 31, 2011$0–
FY2010Dec 31, 2010$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$35.00M+77677.8%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$90.00K-90.4%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$45.00K-80.7%
Q2 FY2022Jun 30, 2022$45.00K-83.1%
Q1 FY2022Mar 31, 2022$940.00K+51.1%
Q4 FY2021Dec 31, 2021$23.00K–
Q3 FY2021Sep 30, 2021$233.00K–
Q2 FY2021Jun 30, 2021$266.00K–
Q1 FY2021Mar 31, 2021$622.00K–

More Actinium Pharmaceuticals figures

See a number that looks wrong?